| 详细介绍：
PC 德国科思创 拜耳 6485GR 901510，价格合理,诚信经营，可全国供货（广东省内免费送上门）。支持物流，快递和货运;支持现金，银行转账交易。
东莞市广业塑胶原料有限公司专业销售原装进口塑胶原料，原厂原包，假一赔十，本司货源稳定充足，发货准时，交期和质量均有保障！是专业塑胶原料供应商！！！可提供COA,SMDS,SGS,COC,UL黄卡和物性表及加工参数。
PC 德国科思创 拜耳 6485GR 901510特性：
PC 德国拜耳6485GR 901510 江苏现货供应PC
|
厂家(产地)
|
德国拜耳
|
牌号
|
6485GR 901510
|
加工级别
|
注塑级
|
|
销售方式
|
品牌经销
|
品牌
|
德国拜耳
|
类型
|
标准料
|
      
PC 德国拜耳 及德国科思创拜耳相关新闻的介绍：
科思创是全球最大的聚合物生产商之一。业务范围主要集中在制造高科技聚合物材料及研发日常生活多领域的创新解决方案。所服务的行业主要包括：汽车、电气和电子、建筑、运动休闲等。
科思创在中国广泛开展业务，建立了遍布全国的销售网络，为本地市场和客户提供高新材料产品及创新解决方案。
在生产领域，投资建立科思创上海一体化基地，至今为止总投资已达30亿欧元，是科思创在亚太地区最大的生产基地。目前，科思创已建成世界级的聚碳酸酯、聚氨酯及涂料、粘合剂、特殊化学品原材料的生产设施，并应用先进和环保的工艺流程及制造技术，降低能耗及减少二氧化碳排放，保证了该基地的可持续发展。
在研发领域，科思创在上海金桥建立科思创聚合物科研开发中心，设有聚碳酸酯、聚氨酯和涂料、粘合剂、特殊化学品等全方位的研发设施，对新应用、新产品进行研发并为客户提供技术支持和培训等服务。
Beijing, April 11, 2017 -
Bayer Group today announced that its prescrtption drug business in China in
2016 has sales of � 1.8 billion * (totaling more than $ 13 billion), an
increase of about 10% from the previous year (based on exchange rate adjustment
), Beyond the market average. "Bayer prescrtption drugs in China to
maintain steady growth, mainly due to our continued focus on China's chronic
disease management to provide leading treatment and solutions, and through
research and innovation to meet China's urgent need to meet the medical
needs," Bayer prescrtption drug business in China and "We will
continue to increase our commitment to China to further enhance the level of
local health care and bring a better life for Chinese patients," said Mr.
Jiang Wei, Executive Vice President and President of Asia Pacific, Asia
Pacific.
At
present, China has been diagnosed with chronic diseases has more than 260
million people [1]. In January 2017, the General Office of the State Council
issued the "Medium and Long-term Plan for Prevention and Treatment of
Chronic Diseases in China (2017-2025)", which proposed two targets for the
prevention and treatment of chronic diseases: by 2020, strive to 30 to 70 years
of age due to cardiovascular and cerebrovascular The premature mortality rate
for diseases, cancer, chronic respiratory disease and diabetes is 10% lower
than 2015; by 20% by 2025 by 2015. With a strong portfolio of products, Bayer
helped China respond to increasingly prominent chronic disease challenges,
including slow disease products such as ibuprofen®, newcomers and newcomers,
for cardiovascular disease and diabetes, Disease prevention and treatment play
an important role, but also to promote the Bayer prescrtption drugs in the Chinese
market's outstanding performance. As a leading new oral anticoagulant in the
Chinese market, Xarelto ® provides a simple anticoagulant treatment option for
Chinese patients in both areas of arterial and venous thrombosis and has made
an important contribution to the growth of Bayer's prescrtption drug business
in China.
Bayer has
also launched a series of innovative health management solutions and treatment
concepts, is committed to improving the health of the Chinese people. Bayer
together with intelligent diabetes management cloud platform operators
"big sugar" launched the "Power +" China's postprandial
blood glucose optimization management platform. Through the mobile medical
service platform, patients can be online real-time interaction with the
exclusive physician health counseling, enjoy more targeted, more personalized
postprandial blood glucose management. And doctors can also closely monitor the
patient's blood sugar levels, according to individual patients to develop a
more accurate blood glucose management program. Not only that, as a leader in
the field of women's health innovation, Bayer actively advocate the treatment
of female hormone balance throughout the management concept, and through the
"miscarriial care" project to Chinese women universal scientific
contraceptive knowledge, to avoid repeated miscarriage injury, five years Six
million abortions benefit from women.
At the
same time, Bayer has continued efforts to ensure the stable supply of
high-quality prescrtption drug products, and thus more effectively meet the
growing demand for chronic disease management. November 2016, Bayer
prescrtption drug Beijing plant integrated expansion project was officially
opened. After the completion of this comprehensive expansion, the overall
capacity of the Beijing plant has doubled to become Bayer's largest prescrtption
drug packaging base in the world, to further ensure that the worship of Tang
Ping ®, thanks to the new with ®, and thanks to aspirin ® enteric-coated
tablets slow Stable supply of therapeutic drugs in China.
"Into
the West" project ushered in the tenth anniversary of the start, promised
to continue to strengthen the support of China's medical and health
infrastructure
Bayer has
long been rooted in the Chinese market, and always insists on supporting
China's commitment to improving the level of primary health care services and
contributing to the construction of the graded clinics. By the National Health
and Family Planning Commission (former Ministry of Health) and Bayer jointly
carried out "into the west" health personnel training project, in
2017 ushered in the tenth anniversary of the project. Since 2007, the project
has been committed to improving the county hospital doctors on the diagnosis
and treatment of common diseases and hospital management staff management
level.
According to the project
evaluation report released by the China Health Economics Institute of Health
Policy and Technology and Economic Evaluation, the "Go to the West"
project has trained more than 35,000 physicians and health managers in 26
provinces and regions across the country. Vice-Chairman Professor Zhao Kun
said: "Bayer as a strong sense of social responsibility and vision of the
enterprise, as early as ten years ago has begun to support China to carry out
grass-roots medical and health capacity-building, especially to improve the
underdeveloped areas of primary health care services Capacity and management
capacity. 'Go to the West' project through ten years of unremitting efforts for
healthy China construction, grading treatment system construction, improve the
medical service action plan to enhance the county hospital service capacity and
other national policies and action plans to make real Feasible contribution,
and for the western grassroots health personnel reserve played an extremely
important role.
PC 德国科思创 拜耳其他型号报价
|
PC
|
德国科思创（拜耳）
|
2865
|
东莞
|
21000
|
|
PC
|
德国科思创（拜耳）
|
3103
|
东莞
|
24200
|
|
PC
|
德国科思创（拜耳）
|
3103
GEF 75/608
|
东莞
|
32000
|
|
PC
|
德国科思创（拜耳）
|
3105
|
东莞
|
25000
|
|
PC
|
德国科思创（拜耳）
|
3107
|
东莞
|
25000
|
|
PC
|
德国科思创（拜耳）
|
3108
|
东莞
|
26800
|
|
PC
|
德国科思创（拜耳）
|
3208
|
东莞
|
30000
|
|
PC
|
德国科思创（拜耳）
|
3413R-131
|
东莞
|
18000
|
|
PC
|
德国科思创（拜耳）
|
6265
|
东莞
|
20000
|
|
PC
|
德国科思创（拜耳）
|
6265
X
|
东莞
|
27000
|
|
PC
|
德国科思创（拜耳）
|
6465
|
东莞
|
23500
|
|
PC
|
德国科思创（拜耳）
|
6485
|
东莞
|
23500
|
|
PC
|
德国科思创（拜耳）
|
6485
BK
|
东莞
|
20000
|
|
PC
|
德国科思创（拜耳）
|
6485GR
901510
|
东莞
|
22000
|
|
PC
|
德国科思创（拜耳）
|
6487
|
东莞
|
27000
|
|
PC
|
德国科思创（拜耳）
|
6555
|
东莞
|
20000
|
|
PC
|
德国科思创（拜耳）
|
6557
|
东莞
|
20000
|
|
PC
|
德国科思创（拜耳）
|
6557
010767
|
东莞
|
22800
|
|
PC
|
德国科思创（拜耳）
|
6557
BK
|
东莞
|
20000
|
|
PC
|
德国科思创（拜耳）
|
6717
|
东莞
|
24800
|
如需了解更多关于PC 德国科思创 拜耳 6485GR 901510的详细信息，欢迎致电联系。
零风险购货10天无理由退换货
为了更好的服务客户，我公司现推出零风险采购方案，你在我公司购买的货物只要发货后10天内。你对货物有任何不满意都可以提出退换申请，在货物未拆封，不影响二次销售的情况下，我司将给你办理退换手续并承担运费，为你免去任何担忧。
塑料当日更新：
4月7日，东莞PC市场气氛清淡，业者买盘谨慎，商谈按需进行。(以下价格均不含税)嘉兴帝人牌号L-1250Y报22700元/吨；奇美牌号110报19500-19600元/吨；台化出光牌号IR2200报19800元/吨。
| 
放大图片
暂无相关下载
